Paper Details

  1. Home
  2. Paper Details

Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review.

Author: BagnascoDiego, PatruccoFilippo, SolidoroPaolo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review compares the effectiveness and safety of different inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) combinations for treating chronic obstructive pulmonary disease (COPD). The review suggests that budesonide/formoterol may be similar to or more effective than other combinations in reducing exacerbations and improving quality of life.
Paper Details　
Original Abstract of the Article :
<b>Introduction</b>: Inhaled corticosteroid (ICS) plus long-acting &#946;<sub>2</sub>-agonist (LABA) combinations are commonly used in the treatment of patients with chronic obstructive pulmonary disease (COPD). At least four fixed-dose ICS/LABA combinations are available, including budesonide/form...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/17476348.2019.1665514

データ提供：米国国立医学図書館（NLM）

Budesonide/Formoterol: A Promising Combination for COPD Management

Chronic obstructive pulmonary disease (COPD) is a debilitating lung disease that causes airflow obstruction and inflammation. Inhaled corticosteroid (ICS) plus long-acting beta-agonist (LABA) combinations are widely used to manage COPD symptoms and reduce exacerbations. This review explores the effectiveness of budesonide/formoterol, a fixed-dose ICS/LABA combination, compared to other available ICS/LABA combinations in treating COPD.

Budesonide/Formoterol: A Competitive Option for COPD Treatment

The review, based on a comprehensive analysis of existing studies, suggests that budesonide/formoterol may be as effective as, or even more effective than, other ICS/LABA combinations in reducing exacerbations and improving quality of life in COPD patients. Additionally, the review highlights that budesonide/formoterol may be associated with a lower incidence of serious pneumonia events and oral candidiasis compared to other ICS/LABA combinations.

Navigating the Complex World of COPD Treatment

This review highlights the importance of choosing the most appropriate ICS/LABA combination for each COPD patient, taking into account their individual needs and preferences. It also emphasizes the need for additional research to definitively compare the different ICS/LABA combinations and provide clear guidance for clinicians. The search for optimal COPD treatment is like a journey through a vast and complex desert, requiring careful consideration of all available options to find the best path for each individual.

Dr. Camel's Conclusion

The world of COPD treatment is like a sprawling desert, filled with various paths and options. Budesonide/formoterol emerges as a promising oasis, offering potentially effective management for COPD symptoms and exacerbations. While more research is needed to fully understand its advantages, this combination holds promise for improving the lives of those living with this challenging disease.

Date :
  1. Date Completed 2020-07-27
  2. Date Revised 2020-07-27
Further Info :

Pubmed ID

31498714

DOI: Digital Object Identifier

10.1080/17476348.2019.1665514

Related Literature

Article Analysis
・Effects of beclomethasone oral inhalation
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.